search
Back to results

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (START)

Primary Purpose

Non-small Cell Lung Cancer

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Tecemotide (L-BLP25)
Single low dose cyclophosphamide
Placebo
Sponsored by
EMD Serono
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring Non-Small Cell Lung Carcinoma;, stage III;, unresectable;, vaccine; Tecemotide; L-BLP25;, Cyclophosphamide;, placebo controlled;, randomized;, double blind;, immunotherapy;

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically or cytologically documented unresectable stage III non-small cell lung cancer (NSCLC)
  • Documented stable disease or objective response, according to Response Evaluation Criteria in Solid Tumors (RECIST), after primary chemoradiotherapy (either sequential or concomitant) for unresectable stage III disease, within 4 weeks (28 days) prior to randomization
  • Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of >=50 Gray (Gy). Subjects must have completed the primary thoracic chemo-radiotherapy at least four weeks (28 days) and no later than 12 weeks (84 days) prior to randomization. Subjects who received prophylactic brain irradiation as part of primary chemo-radiotherapy are eligible
  • Geographically accessible for ongoing follow-up, and committed to comply with the designated visits
  • An Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • A platelet count > 140 x 10^9/Liter; white blood cells (WBC) > 2.5 x 10^9/Liter and hemoglobin > 90 gram per liter (g/L)

Exclusion Criteria:

Pre-Therapies:

  • Undergone lung cancer specific therapy (including surgery) other than primary chemo-radiotherapy
  • Receipt of immunotherapy (e.g. interferons, tumor necrosis factor [TNF], interleukins, or biological response modifiers [granulocyte macrophage colony stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating factor {M-CSF}], monoclonal antibodies) within 4 weeks (28 days) prior to randomization
  • Receipt of investigational systemic drugs (including off-label use of approved products) within 4 weeks (28 days) prior to randomization

Disease Status:

  • Metastatic disease
  • Malignant pleural effusion at initial diagnosis and/or at study entry
  • Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
  • Autoimmune disease
  • A recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or congenital immunodeficiencies
  • Any preexisting medical condition requiring chronic steroid or immunosuppressive therapy (steroids for the treatment of radiation pneumonitis are allowed)
  • Known Hepatitis B and/or C

Physiological Functions:

  • Clinically significant hepatic dysfunction
  • Clinically significant renal dysfunction
  • Clinically significant cardiac disease
  • Splenectomy
  • Infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response

Standard Safety:

  • Pregnant or breast-feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator
  • Known drug abuse/alcohol abuse
  • Legal incapacity or limited legal capacity

Sites / Locations

  • Saint Edward Mercy Medical Center
  • Pacific Cancer Medical Center
  • Glendale Adventist Medical Center
  • Norris Cancer Hospital
  • Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute
  • Clinical Trials and Research Associates, Inc.
  • Desert Hematology Oncology Medical Group, Inc
  • Stockton Hematology Oncology Medical Group, Inc.
  • University of Colorado Cancer Center
  • Pasco Hernando Oncology Associates P.A
  • University of Miami, Sylvester Comprehensive Cancer Center
  • Pasco Hernando Oncology Associates, PA
  • Florida Hospital Memorial System
  • Southern Illinois Hematology/Oncology
  • Rush University Medical Center
  • Joliet Oncology-Hematology Associates, Ltd.
  • Kentucky Cancer Center
  • Leonard J. Chabert Medical Center
  • Hematology and Oncology Specialists, LLC
  • Sinai Hospital of Baltimore
  • University of Maryland, Marlene and Steward Greenbaum Cancer Center
  • Lahey Clinic
  • Oncology Care Associates
  • University of Minnesota Physicians, Masonic Cancer Center
  • Saint Louis University Cance Center
  • Deaconess Billings Clinic
  • Big Sky Oncology, Sletten Cancer Institute
  • Nebraska Cancer Care, LLC
  • Southeast Nebraska Cancer Center
  • St. Vincents Comprehensive Cancer Center
  • Hematology Oncology Associates of Rockland
  • Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
  • Carolinas Hematology-Oncology
  • Hanover Medical Specialts PA
  • Gabrail Cancer Center
  • University Hospitals of Cleveland
  • Signal Point Clinical Research Center, LLC
  • Southwestern Regional Medical Center
  • Southwestern Regional Medical Center
  • Providence Portland Medical Center
  • Univ. of Pennsylvania Abramson Cancer Center
  • Fox Chase Cancer Center
  • The Jones Clinic, PC
  • Center for Oncology Research
  • John Peter Smith Center for Cancer Care
  • The Center for Cancer and Blood Disorders
  • Cancer Therapy & Research Center, Institute for Drug Development
  • Fairfax-Northern Virginia Hematology Oncology, PC
  • Wheeling Hospital
  • Hospital Italiano Regional del Sur
  • Paliar
  • Corporacion Medica General San Martin
  • Centro Oncologico de Roario
  • Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
  • Instituto Especializado Alexander Fleming
  • Sociedad Intaliana de Beneficencia en Buenos Aires, Hospital Italiano
  • Clinica Universitaria Reina Fabiola
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Nugieo de Oncologia da Bahia
  • Hospital das Clinicas da Faculdade de Medinina de Univeridade
  • Hospital LifeCenter
  • Hospital Nossa Senhora da Conceicao, Centro de Pesquisas Medicas e Ensaios Clinicos
  • Associacao Hospital de Caridade Ijui
  • Hospital de Clinicas de Porto Alegre, Dept. de Endocrinologia
  • Hospital Sao Lucas-Pucrs
  • Research Site
  • Centro de Oncologia de Campinas - OCC
  • Fundacao Hospital Amaral Carvalho
  • Instituto de Oncologia de Sorocaba
  • Research Site
  • Instituto Nacional do Cancer - INCA
  • Instituto do Cancer Arnaldo Vieira de Caralho-Onco-pneumonia
  • Santa Casa de Misericordia De Sao Paulo
  • Tom Baker Cancer Center
  • Cross Cancer Institue
  • Frazer Valley Cancer Center
  • British Columbia Cancer Agency
  • Vancouver Island Cancer Center
  • Cancer Care Manitoba
  • Capital District Health Authority
  • Cape Breton Districk Health Authority Cancer Care
  • Juravinski Cancer Center
  • Niagara Health System
  • Thunder Bay Regional Health Science Center Northwestern Ontario Regional Center
  • Mount Sinai Hospital
  • Princess Margaret Hospital
  • Windsor Regional Cancer Center
  • Hopital Notre Dame
  • Jewish General Hospital
  • Hopital Laval
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Reseach Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Consultorio del
  • Centro Oncologico de Chihuahua
  • Instituto Nacional de Cancerologia (INCAN)
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Genova
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Genova
  • Research Site
  • Research Site
  • Genova
  • Genova
  • Genova
  • Genova
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Reseaerch Site
  • Research Site
  • Research Site
  • Genova
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Tecemotide (L-BLP25)

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Overall Survival
Overall survival time was defined as the time from randomization to death. Participants without events were censored at the last date they were known to be alive or the clinical cut-off date, whatever was earlier.

Secondary Outcome Measures

Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)
Time to symptom progression (TTSP) was measured by LCSS. Symptomatic progression was defined as an increase (worsening) of the Average Symptomatic Burden Index (ASBI that is, the mean of the six major lung cancer specific symptom scores of the LCSS patient scale - ranging from 0 to 100 where higher score indicates worst outcome). Worsening was defined as a 10% increase in the scale breadth from the baseline score. TTSP is defined as the time from randomization to worsening in ASBI. Participants without event are censored at the date of the last LCSS assessment.
Time To Progression (TTP)
Time from randomization to disease progression. Disease progression was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 [RECIST v1.0]) as at least a 20% increase in the sum of the longest diameter of target lesions from nadir, or the appearance of one or more new lesions.
One-, Two- and Three-year Survival Rate
The percentages of participants who were alive at 1, 2, and 3 years were calculated as a cumulative percentage by Kaplan-Meier survival analysis approach.
Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions
Treatment -emergent adverse events were defined as those with onset or worsening occurring at or after the first dosing day of study medication and up to 42 days after the last administration of any study drug or the clinical cut-off date. Injection site reactions were reported as assessed by the Investigator.

Full Information

First Posted
December 7, 2006
Last Updated
October 19, 2015
Sponsor
EMD Serono
Collaborators
Merck KGaA, Darmstadt, Germany
search

1. Study Identification

Unique Protocol Identification Number
NCT00409188
Brief Title
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Acronym
START
Official Title
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
EMD Serono
Collaborators
Merck KGaA, Darmstadt, Germany

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Detailed Description
Ancillary Trial: An exploratory investigation of immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination. The ancillary study is a sub-study within START. This is an exploratory investigation of the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination. The main objective is to evaluate whether administration of single-shot, low-dose cyclophosphamide followed by tecemotide (L-BLP25) vaccinations induces specific immune response in peripheral blood to BLP25 (the mucinous glycoprotein 1 [MUC1] antigen) as well as a modulation of cellular and soluble components of the immune response in subjects with unresectable stage III NSCLC. Twenty-five of the European START sites will participate in the ancillary study. Sample size: up to 60 to 80 subjects All inclusion criteria specified in the START clinical trial protocol except for hemoglobin >= 100 gram/Liter (g/L) All exclusion criteria are the same as specified in the START clinical trial protocol Schedule of events: Blood samples will be taken at baseline, visit week 4, 8 13 and 25 (80 milliliter (mL) whole blood each)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer
Keywords
Non-Small Cell Lung Carcinoma;, stage III;, unresectable;, vaccine; Tecemotide; L-BLP25;, Cyclophosphamide;, placebo controlled;, randomized;, double blind;, immunotherapy;

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1513 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tecemotide (L-BLP25)
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
Tecemotide (L-BLP25)
Intervention Description
After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
Intervention Type
Drug
Intervention Name(s)
Single low dose cyclophosphamide
Intervention Description
A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
Primary Outcome Measure Information:
Title
Overall Survival
Description
Overall survival time was defined as the time from randomization to death. Participants without events were censored at the last date they were known to be alive or the clinical cut-off date, whatever was earlier.
Time Frame
Up to 66 months
Secondary Outcome Measure Information:
Title
Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)
Description
Time to symptom progression (TTSP) was measured by LCSS. Symptomatic progression was defined as an increase (worsening) of the Average Symptomatic Burden Index (ASBI that is, the mean of the six major lung cancer specific symptom scores of the LCSS patient scale - ranging from 0 to 100 where higher score indicates worst outcome). Worsening was defined as a 10% increase in the scale breadth from the baseline score. TTSP is defined as the time from randomization to worsening in ASBI. Participants without event are censored at the date of the last LCSS assessment.
Time Frame
Up to 66 months
Title
Time To Progression (TTP)
Description
Time from randomization to disease progression. Disease progression was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 [RECIST v1.0]) as at least a 20% increase in the sum of the longest diameter of target lesions from nadir, or the appearance of one or more new lesions.
Time Frame
Up to 66 months
Title
One-, Two- and Three-year Survival Rate
Description
The percentages of participants who were alive at 1, 2, and 3 years were calculated as a cumulative percentage by Kaplan-Meier survival analysis approach.
Time Frame
Years 1, 2, and 3
Title
Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions
Description
Treatment -emergent adverse events were defined as those with onset or worsening occurring at or after the first dosing day of study medication and up to 42 days after the last administration of any study drug or the clinical cut-off date. Injection site reactions were reported as assessed by the Investigator.
Time Frame
From first dose up to 42 days after the last dose of the trial treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically documented unresectable stage III non-small cell lung cancer (NSCLC) Documented stable disease or objective response, according to Response Evaluation Criteria in Solid Tumors (RECIST), after primary chemoradiotherapy (either sequential or concomitant) for unresectable stage III disease, within 4 weeks (28 days) prior to randomization Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of >=50 Gray (Gy). Subjects must have completed the primary thoracic chemo-radiotherapy at least four weeks (28 days) and no later than 12 weeks (84 days) prior to randomization. Subjects who received prophylactic brain irradiation as part of primary chemo-radiotherapy are eligible Geographically accessible for ongoing follow-up, and committed to comply with the designated visits An Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 A platelet count > 140 x 10^9/Liter; white blood cells (WBC) > 2.5 x 10^9/Liter and hemoglobin > 90 gram per liter (g/L) Exclusion Criteria: Pre-Therapies: Undergone lung cancer specific therapy (including surgery) other than primary chemo-radiotherapy Receipt of immunotherapy (e.g. interferons, tumor necrosis factor [TNF], interleukins, or biological response modifiers [granulocyte macrophage colony stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating factor {M-CSF}], monoclonal antibodies) within 4 weeks (28 days) prior to randomization Receipt of investigational systemic drugs (including off-label use of approved products) within 4 weeks (28 days) prior to randomization Disease Status: Metastatic disease Malignant pleural effusion at initial diagnosis and/or at study entry Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years Autoimmune disease A recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or congenital immunodeficiencies Any preexisting medical condition requiring chronic steroid or immunosuppressive therapy (steroids for the treatment of radiation pneumonitis are allowed) Known Hepatitis B and/or C Physiological Functions: Clinically significant hepatic dysfunction Clinically significant renal dysfunction Clinically significant cardiac disease Splenectomy Infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response Standard Safety: Pregnant or breast-feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator Known drug abuse/alcohol abuse Legal incapacity or limited legal capacity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Responsible
Organizational Affiliation
EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany
Official's Role
Study Director
Facility Information:
Facility Name
Saint Edward Mercy Medical Center
City
Fort Smith
State/Province
Arkansas
ZIP/Postal Code
72901
Country
United States
Facility Name
Pacific Cancer Medical Center
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Glendale Adventist Medical Center
City
Glendale
State/Province
California
ZIP/Postal Code
91206
Country
United States
Facility Name
Norris Cancer Hospital
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Clinical Trials and Research Associates, Inc.
City
Montebello
State/Province
California
ZIP/Postal Code
90640
Country
United States
Facility Name
Desert Hematology Oncology Medical Group, Inc
City
Rancho Mirage
State/Province
California
Country
United States
Facility Name
Stockton Hematology Oncology Medical Group, Inc.
City
Stockton
State/Province
California
ZIP/Postal Code
95204
Country
United States
Facility Name
University of Colorado Cancer Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Pasco Hernando Oncology Associates P.A
City
Brooksville
State/Province
Florida
ZIP/Postal Code
34613
Country
United States
Facility Name
University of Miami, Sylvester Comprehensive Cancer Center
City
Miami
State/Province
Florida
Country
United States
Facility Name
Pasco Hernando Oncology Associates, PA
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34652
Country
United States
Facility Name
Florida Hospital Memorial System
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32174
Country
United States
Facility Name
Southern Illinois Hematology/Oncology
City
Centralia
State/Province
Illinois
ZIP/Postal Code
62801
Country
United States
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Joliet Oncology-Hematology Associates, Ltd.
City
Joliet
State/Province
Illinois
ZIP/Postal Code
60435
Country
United States
Facility Name
Kentucky Cancer Center
City
Hazard
State/Province
Kentucky
ZIP/Postal Code
41701
Country
United States
Facility Name
Leonard J. Chabert Medical Center
City
Houma
State/Province
Louisiana
Country
United States
Facility Name
Hematology and Oncology Specialists, LLC
City
Metarie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Sinai Hospital of Baltimore
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21215
Country
United States
Facility Name
University of Maryland, Marlene and Steward Greenbaum Cancer Center
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Lahey Clinic
City
Burlington
State/Province
Massachusetts
Country
United States
Facility Name
Oncology Care Associates
City
Saint Joseph
State/Province
Michigan
ZIP/Postal Code
49085
Country
United States
Facility Name
University of Minnesota Physicians, Masonic Cancer Center
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
Saint Louis University Cance Center
City
Saint Louis
State/Province
Missouri
Country
United States
Facility Name
Deaconess Billings Clinic
City
Billings
State/Province
Montana
ZIP/Postal Code
59101
Country
United States
Facility Name
Big Sky Oncology, Sletten Cancer Institute
City
Great Falls
State/Province
Montana
ZIP/Postal Code
59405
Country
United States
Facility Name
Nebraska Cancer Care, LLC
City
Hastings
State/Province
Nebraska
ZIP/Postal Code
68901
Country
United States
Facility Name
Southeast Nebraska Cancer Center
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68510
Country
United States
Facility Name
St. Vincents Comprehensive Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10011
Country
United States
Facility Name
Hematology Oncology Associates of Rockland
City
Nyack
State/Province
New York
ZIP/Postal Code
10960
Country
United States
Facility Name
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
Carolinas Hematology-Oncology
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
Facility Name
Hanover Medical Specialts PA
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Gabrail Cancer Center
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Facility Name
University Hospitals of Cleveland
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Signal Point Clinical Research Center, LLC
City
Middletown
State/Province
Ohio
ZIP/Postal Code
45042
Country
United States
Facility Name
Southwestern Regional Medical Center
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74133
Country
United States
Facility Name
Southwestern Regional Medical Center
City
Tulsa
State/Province
Oklahoma
Country
United States
Facility Name
Providence Portland Medical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Facility Name
Univ. of Pennsylvania Abramson Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Facility Name
The Jones Clinic, PC
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
Center for Oncology Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
John Peter Smith Center for Cancer Care
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
The Center for Cancer and Blood Disorders
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
Cancer Therapy & Research Center, Institute for Drug Development
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Fairfax-Northern Virginia Hematology Oncology, PC
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Facility Name
Wheeling Hospital
City
Wheeling
State/Province
West Virginia
ZIP/Postal Code
26003
Country
United States
Facility Name
Hospital Italiano Regional del Sur
City
Bahia Blanca
State/Province
Buenos Aires
Country
Argentina
Facility Name
Paliar
City
Capital, Buenos Aires
State/Province
Buenos Aires
Country
Argentina
Facility Name
Corporacion Medica General San Martin
City
San Martin
State/Province
Buenos Aires
Country
Argentina
Facility Name
Centro Oncologico de Roario
City
Rosario
State/Province
Santa Fe
Country
Argentina
Facility Name
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
City
Ciudad Autonoma de Buenos Aires
Country
Argentina
Facility Name
Instituto Especializado Alexander Fleming
City
Ciudad Autonoma de Buenos Aires
Country
Argentina
Facility Name
Sociedad Intaliana de Beneficencia en Buenos Aires, Hospital Italiano
City
Ciudad Autonoma de Buenos Aires
Country
Argentina
Facility Name
Clinica Universitaria Reina Fabiola
City
Cordoba
Country
Argentina
Facility Name
Research Site
City
Tandil
Country
Argentina
Facility Name
Research Site
City
Nedlands
State/Province
Western Australia
Country
Australia
Facility Name
Research Site
City
Bankstown, NSW
Country
Australia
Facility Name
Research Site
City
Camperdown
Country
Australia
Facility Name
Research Site
City
Heidelberg
Country
Australia
Facility Name
Research Site
City
Kingswood
Country
Australia
Facility Name
Research Site
City
Saint Leonards
Country
Australia
Facility Name
Research Site
City
Woolloongabba
Country
Australia
Facility Name
Research Site
City
Graz
State/Province
Styria
Country
Austria
Facility Name
Research Site
City
Linz
State/Province
Upper Austria
Country
Austria
Facility Name
Research Site
City
Inssbruck
Country
Austria
Facility Name
Research Site
City
Salzburg
Country
Austria
Facility Name
Research Site
City
Wein, Venna
Country
Austria
Facility Name
Research Site
City
Wels
Country
Austria
Facility Name
Research Site
City
Wien
Country
Austria
Facility Name
Research Site
City
Brasschaat
Country
Belgium
Facility Name
Research Site
City
Brussels
Country
Belgium
Facility Name
Research Site
City
Haine-Saint Paul
Country
Belgium
Facility Name
Research Site
City
Leuven
Country
Belgium
Facility Name
Research Site
City
Liege
Country
Belgium
Facility Name
Research Site
City
Mechelen
Country
Belgium
Facility Name
Nugieo de Oncologia da Bahia
City
Salvador
State/Province
Bahia
Country
Brazil
Facility Name
Hospital das Clinicas da Faculdade de Medinina de Univeridade
City
São Paulo
State/Province
De ao Paulo
Country
Brazil
Facility Name
Hospital LifeCenter
City
Belo Horizonte
State/Province
Minas Gerais
Country
Brazil
Facility Name
Hospital Nossa Senhora da Conceicao, Centro de Pesquisas Medicas e Ensaios Clinicos
City
Porto Alegre
State/Province
Rio Grande Do Sol
Country
Brazil
Facility Name
Associacao Hospital de Caridade Ijui
City
Ijuí
State/Province
Rio Grande Do Sul
Country
Brazil
Facility Name
Hospital de Clinicas de Porto Alegre, Dept. de Endocrinologia
City
Porto Alegre
State/Province
Rio Grande Do Sul
Country
Brazil
Facility Name
Hospital Sao Lucas-Pucrs
City
Porto Alegre
State/Province
Rio Grande Do Sul
Country
Brazil
Facility Name
Research Site
City
Porto Algre
State/Province
Rio Grande Do Sul
Country
Brazil
Facility Name
Centro de Oncologia de Campinas - OCC
City
Campinas
State/Province
Sao Paulo
Country
Brazil
Facility Name
Fundacao Hospital Amaral Carvalho
City
Jau
State/Province
Sao Paulo
Country
Brazil
Facility Name
Instituto de Oncologia de Sorocaba
City
Sorocaba
State/Province
Sao Paulo
Country
Brazil
Facility Name
Research Site
City
Ondina-Salvdor
Country
Brazil
Facility Name
Instituto Nacional do Cancer - INCA
City
Rio de Janeriro
Country
Brazil
Facility Name
Instituto do Cancer Arnaldo Vieira de Caralho-Onco-pneumonia
City
Sao Paulo
Country
Brazil
Facility Name
Santa Casa de Misericordia De Sao Paulo
City
Sao Paulo
Country
Brazil
Facility Name
Tom Baker Cancer Center
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
Cross Cancer Institue
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
Frazer Valley Cancer Center
City
Surrey
State/Province
British Columbia
Country
Canada
Facility Name
British Columbia Cancer Agency
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
Vancouver Island Cancer Center
City
Victoria
State/Province
British Columbia
Country
Canada
Facility Name
Cancer Care Manitoba
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
Capital District Health Authority
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
Cape Breton Districk Health Authority Cancer Care
City
Sydney
State/Province
Nova Scotia
Country
Canada
Facility Name
Juravinski Cancer Center
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
Niagara Health System
City
Saint Catharines
State/Province
Ontario
Country
Canada
Facility Name
Thunder Bay Regional Health Science Center Northwestern Ontario Regional Center
City
Thunder Bay
State/Province
Ontario
Country
Canada
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Princess Margaret Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Windsor Regional Cancer Center
City
Windsor
State/Province
Ontario
Country
Canada
Facility Name
Hopital Notre Dame
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
Hopital Laval
City
Sainte-Foy
State/Province
Quebec
Country
Canada
Facility Name
Research Site
City
Beijing
Country
China
Facility Name
Research Site
City
Guangzhou
Country
China
Facility Name
Research Site
City
Shanghai
Country
China
Facility Name
Research Site
City
Hradec Králové
Country
Czech Republic
Facility Name
Research Site
City
Ostrava-Poruba
Country
Czech Republic
Facility Name
Research Site
City
Prague
Country
Czech Republic
Facility Name
Research Site
City
Praha 2
Country
Czech Republic
Facility Name
Research Site
City
Praha
Country
Czech Republic
Facility Name
Research Site
City
Usti nad Labem
Country
Czech Republic
Facility Name
Research Site
City
Herlev
Country
Denmark
Facility Name
Research Site
City
Odense C
Country
Denmark
Facility Name
Research Site
City
Besancon
State/Province
Franche-Comte
Country
France
Facility Name
Research Site
City
Pierre-Benite Cedex
State/Province
Rhone-Alpes
Country
France
Facility Name
Research Site
City
Beuvry
Country
France
Facility Name
Research Site
City
Brest
Country
France
Facility Name
Research Site
City
Caen
Country
France
Facility Name
Research Site
City
Chauny
Country
France
Facility Name
Research Site
City
Marseille Cedex
Country
France
Facility Name
Research Site
City
Marseille
Country
France
Facility Name
Research Site
City
Nancy
Country
France
Facility Name
Research Site
City
Nantes-Saint Herblain
Country
France
Facility Name
Research Site
City
Paris Cedex 15
Country
France
Facility Name
Research Site
City
Perpignan
Country
France
Facility Name
Research Site
City
Poitiers Cedex
Country
France
Facility Name
Research Site
City
Strasbourg Cedex
Country
France
Facility Name
Research Site
City
Essen
State/Province
Nordrhein-Westfalen
Country
Germany
Facility Name
Research Site
City
Hemer
State/Province
Nordrhein-Westfalen
Country
Germany
Facility Name
Research Site
City
Mainz
State/Province
Rheinland-Pfalz
Country
Germany
Facility Name
Research Site
City
Homburg
State/Province
Saar
Country
Germany
Facility Name
Research Site
City
Berlin
Country
Germany
Facility Name
Research Site
City
Coswig
Country
Germany
Facility Name
Research Site
City
Essen
Country
Germany
Facility Name
Research Site
City
Frankfurt am Main
Country
Germany
Facility Name
Research Site
City
Freiburg
Country
Germany
Facility Name
Research Site
City
Gauting
Country
Germany
Facility Name
Research Site
City
Großhansdorf
Country
Germany
Facility Name
Research Site
City
Hamburg
Country
Germany
Facility Name
Reseach Site
City
Heidelberg
Country
Germany
Facility Name
Research Site
City
Kassel
Country
Germany
Facility Name
Research Site
City
Kiel
Country
Germany
Facility Name
Research Site
City
Koln
Country
Germany
Facility Name
Research Site
City
Leipzig
Country
Germany
Facility Name
Research Site
City
Magdeburg
Country
Germany
Facility Name
Research Site
City
Mainz
Country
Germany
Facility Name
Research Site
City
Minden
Country
Germany
Facility Name
Research Site
City
Muchen
Country
Germany
Facility Name
Research Site
City
München
Country
Germany
Facility Name
Research Site
City
Oldenburg
Country
Germany
Facility Name
Research Site
City
Rostock
Country
Germany
Facility Name
Research Site
City
Maroussi
State/Province
Athens
Country
Greece
Facility Name
Research Site
City
Athens
State/Province
Attica
Country
Greece
Facility Name
Research Site
City
Thessaloniki
State/Province
Nea Efkarpia
Country
Greece
Facility Name
Research Site
City
Athens
Country
Greece
Facility Name
Research Site
City
Chidari, Athens
Country
Greece
Facility Name
Research Site
City
Heraklion
Country
Greece
Facility Name
Research Site
City
Shatin
State/Province
New Territories
Country
Hong Kong
Facility Name
Research Site
City
Hong Kong
Country
Hong Kong
Facility Name
Research Site
City
Budapest
Country
Hungary
Facility Name
Research Site
City
Mátraháza
Country
Hungary
Facility Name
Research Site
City
Nyíregyháza
Country
Hungary
Facility Name
Research Site
City
Tatabayana
Country
Hungary
Facility Name
Research Site
City
Chennai
Country
India
Facility Name
Research Site
City
Hyderabad
Country
India
Facility Name
Research Site
City
Mumbai
Country
India
Facility Name
Research Site
City
New Delhi
Country
India
Facility Name
Research Site
City
Vellore
Country
India
Facility Name
Research Site
City
Dublin
Country
Ireland
Facility Name
Research Site
City
Tel Hashomer
State/Province
Tel Avir
Country
Israel
Facility Name
Research Site
City
Beer Sheva
Country
Israel
Facility Name
Research Site
City
Haifa
Country
Israel
Facility Name
Research Site
City
Jerusalem
Country
Israel
Facility Name
Research Site
City
Kfar Saba
Country
Israel
Facility Name
Research Site
City
Petach Tikva
Country
Israel
Facility Name
Research Site
City
Tel Aviv
Country
Israel
Facility Name
Research Site
City
Zerifin
Country
Israel
Facility Name
Research Site
City
Candiolo
State/Province
Torino
Country
Italy
Facility Name
Research Site
City
Avelino
Country
Italy
Facility Name
Research Site
City
Bologna
Country
Italy
Facility Name
Research Site
City
Carpi
Country
Italy
Facility Name
Research Site
City
Chieti
Country
Italy
Facility Name
Research Site
City
Forli
Country
Italy
Facility Name
Research Site
City
Genova
Country
Italy
Facility Name
Research Site
City
Meldola
Country
Italy
Facility Name
Research Site
City
Milano
Country
Italy
Facility Name
Research Site
City
Napoli
Country
Italy
Facility Name
Research Site
City
Orbassano-Torino
Country
Italy
Facility Name
Research Site
City
Palermo
Country
Italy
Facility Name
Research Site
City
Parma
Country
Italy
Facility Name
Research Site
City
Rome
Country
Italy
Facility Name
Research Site
City
Rozzano-Milano
Country
Italy
Facility Name
Research Site
City
Sassari
Country
Italy
Facility Name
Research Site
City
Trento
Country
Italy
Facility Name
Research Site
City
Goyang-si
State/Province
Gyeonggi-do
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
State/Province
Gyeonggi-Do
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
Country
Korea, Republic of
Facility Name
Consultorio del
City
Morelia
State/Province
Michoacan
Country
Mexico
Facility Name
Centro Oncologico de Chihuahua
City
Chihuahua
Country
Mexico
Facility Name
Instituto Nacional de Cancerologia (INCAN)
City
Mexico City
Country
Mexico
Facility Name
Research Site
City
Amsterdam
State/Province
Noord-Holland
Country
Netherlands
Facility Name
Research Site
City
Amsterdam
Country
Netherlands
Facility Name
Research Site
City
Eindhoven
Country
Netherlands
Facility Name
Research Site
City
Hoofdrop
Country
Netherlands
Facility Name
Research Site
City
Tilburg
Country
Netherlands
Facility Name
Research Site
City
Zwolle
Country
Netherlands
Facility Name
Research Site
City
Warszawa
State/Province
Mazowieckie
Country
Poland
Facility Name
Research Site
City
Bialystok
Country
Poland
Facility Name
Research Site
City
Bydgoszcz
Country
Poland
Facility Name
Research Site
City
Bytom
Country
Poland
Facility Name
Research Site
City
Gdynia
Country
Poland
Facility Name
Research Site
City
Kraków
Country
Poland
Facility Name
Genova
City
Lodz
Country
Poland
Facility Name
Research Site
City
Olsztyn
Country
Poland
Facility Name
Research Site
City
Otwock
Country
Poland
Facility Name
Research Site
City
Poznan
Country
Poland
Facility Name
Research Site
City
Torun
Country
Poland
Facility Name
Research Site
City
Warsaw
Country
Poland
Facility Name
Genova
City
Warszawa
Country
Poland
Facility Name
Research Site
City
Wroclaw
Country
Poland
Facility Name
Research Site
City
Zabrze
Country
Poland
Facility Name
Genova
City
Coimbra
Country
Portugal
Facility Name
Genova
City
Lisboa
Country
Portugal
Facility Name
Genova
City
Porto
Country
Portugal
Facility Name
Genova
City
Santa Maria de Feira
Country
Portugal
Facility Name
Research Site
City
Bucharest
Country
Romania
Facility Name
Research Site
City
Bucuresti
Country
Romania
Facility Name
Research Site
City
Cluj-Napoca
Country
Romania
Facility Name
Research Site
City
Iasi
Country
Romania
Facility Name
Research Site
City
Sibiu
Country
Romania
Facility Name
Research Site
City
Suceava
Country
Romania
Facility Name
Research Site
City
Timisoara
Country
Romania
Facility Name
Reseaerch Site
City
Kazan
State/Province
Tatarstan
Country
Russian Federation
Facility Name
Research Site
City
Yaroslavl
State/Province
Yaroslavlr
Country
Russian Federation
Facility Name
Research Site
City
Barnaul
Country
Russian Federation
Facility Name
Genova
City
Chelaybinsk
Country
Russian Federation
Facility Name
Research Site
City
Ivanovo
Country
Russian Federation
Facility Name
Research Site
City
Kazan
Country
Russian Federation
Facility Name
Research Site
City
Moscow
Country
Russian Federation
Facility Name
Research Site
City
Obninsk
Country
Russian Federation
Facility Name
Research Site
City
Saint Petersburg
Country
Russian Federation
Facility Name
Research Site
City
Tomsk
Country
Russian Federation
Facility Name
Research Site
City
Voronezh
Country
Russian Federation
Facility Name
Research Site
City
Singapore
Country
Singapore
Facility Name
Research Site
City
Bratislava
Country
Slovakia
Facility Name
Research Site
City
Kosice
Country
Slovakia
Facility Name
Research Site
City
Nitra
Country
Slovakia
Facility Name
Research Site
City
Mataro
State/Province
Barcelona
Country
Spain
Facility Name
Research Site
City
Barakaldo
State/Province
Bilbao
Country
Spain
Facility Name
Research Site
City
Donostia-San Sebastian
State/Province
Guipuzcoa
Country
Spain
Facility Name
Research Site
City
A Coruna
Country
Spain
Facility Name
Research Site
City
Alicante
Country
Spain
Facility Name
Research Site
City
Barcelona
Country
Spain
Facility Name
Research Site
City
Burgos
Country
Spain
Facility Name
Research Site
City
Girona
Country
Spain
Facility Name
Research Site
City
Jaen
Country
Spain
Facility Name
Research Site
City
Lugo
Country
Spain
Facility Name
Research Site
City
Madrid
Country
Spain
Facility Name
Research Site
City
Malaga
Country
Spain
Facility Name
Research Site
City
Gävle
Country
Sweden
Facility Name
Research Site
City
Göteborg
Country
Sweden
Facility Name
Research Site
City
Lund
Country
Sweden
Facility Name
Research Site
City
Stockholm
Country
Sweden
Facility Name
Research Site
City
Umea
Country
Sweden
Facility Name
Research Site
City
Uppsala
Country
Sweden
Facility Name
Research Site
City
Basel
Country
Switzerland
Facility Name
Research Site
City
Geneve
Country
Switzerland
Facility Name
Research Site
City
Genève
Country
Switzerland
Facility Name
Research Site
City
Winterthur
Country
Switzerland
Facility Name
Research Site
City
Kaohsiung
Country
Taiwan
Facility Name
Research Site
City
Taichung
Country
Taiwan
Facility Name
Research Site
City
Tainan
Country
Taiwan
Facility Name
Research Site
City
Taipei
Country
Taiwan
Facility Name
Research Site
City
Tao-Yuan
Country
Taiwan
Facility Name
Research Site
City
Cornwall
Country
United Kingdom
Facility Name
Research Site
City
Edinburgh
Country
United Kingdom
Facility Name
Research Site
City
Glasgow
Country
United Kingdom
Facility Name
Research Site
City
Guildford
Country
United Kingdom
Facility Name
Research Site
City
Inverness
Country
United Kingdom
Facility Name
Research Site
City
Leeds
Country
United Kingdom
Facility Name
Research Site
City
Leicester
Country
United Kingdom
Facility Name
Research Site
City
London
Country
United Kingdom
Facility Name
Research Site
City
Manchester
Country
United Kingdom
Facility Name
Research Site
City
Southampton
Country
United Kingdom
Facility Name
Research Site
City
Surrey
Country
United Kingdom
Facility Name
Research Site
City
Torquay
Country
United Kingdom
Facility Name
Research Site
City
Wirral
Country
United Kingdom

12. IPD Sharing Statement

Citations:
Citation
Butts C, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Helwig C, Falk MH, Shepherd FA. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. American Society of Clinical Oncology - 49th Annual Meeting. 2013; Abstr No. 7500.
Results Reference
background
Citation
Shepherd FA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Helwig C, Schroeder A, Butts C. Updated analysis and secondary endpoints with L-BLP25 in unresectable stage III non-small cell lung cancer in the phase III START study. European Society for Medical Oncology 38th Congress - ECCO 17, ESMO 38, ESTRO 32. 2013. Abstr No. 3419.
Results Reference
background
Citation
Mitchell P, Butts C, Socinski M, Thatcher N, Wichardt-Johansson G, Ellis P, Gladkov O, Pereira J, Eberhardt W, Horwood K, Szczesna A, Helwig C, Schröder A, Shepherd F. Tecemotide (L-BLP25) in unresectable stage III non-small cell lung cancer in the phase III START study: Further endpoint and exploratory biomarker results. World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2779.
Results Reference
background
Citation
Thatcher N, Shepherd FA, Mitchell P, Socinski MA, Paredes A, Lambrechts M, Thomas M, Kollmeier J, Zemanová M, Sadjadian P, Peylan-Ramu N, Helwig C, Schröder A, Butts C. Geographic differences in the combined-modality treatment of stage III unresectable non-small cell lung cancer: Results from a global phase III trial of tecemotide (L-BLP25). World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2712.
Results Reference
background
Citation
Socinski M, Butts C, Mitchell P, Thatcher N, Scagliotti G, Robinet G, Martin C, Zukin M, Ragulin Y, Bonomi P, Yang CH, Regnault A, Helwig C, de Nigris E, Shepherd F. Exploration of patient health status as measured by the generic preference-based questionnaire EQ-5D alongside the START trial of tecemotide in non-small cell lung cancer. World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2744.
Results Reference
background
PubMed Identifier
24331154
Citation
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schroder A, Shepherd FA; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.
Results Reference
result
PubMed Identifier
24976972
Citation
DeGregorio M, Soe L, Wolf M. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis. 2014 Jun;6(6):571-3. doi: 10.3978/j.issn.2072-1439.2014.05.15. No abstract available.
Results Reference
result
PubMed Identifier
34870327
Citation
Zhu J, Yuan Y, Wan X, Yin D, Li R, Chen W, Suo C, Song H. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub3.
Results Reference
derived
PubMed Identifier
25722382
Citation
Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martin C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015 Jun;26(6):1134-1142. doi: 10.1093/annonc/mdv104. Epub 2015 Feb 26.
Results Reference
derived

Learn more about this trial

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

We'll reach out to this number within 24 hrs